Enliven Therapeutics (ELVN) Stock Price, News & Analysis

Company Overview

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications. Enliven applies structure-guided drug design and advanced screening technologies to optimize potency, selectivity and oral bioavailability of its lead compounds. Preclinical studies have demonstrated proof-of-concept in multiple tumor models, supporting planned clinical investigations aimed at overcoming resistance mechanisms that limit the efficacy of conventional therapies.

Headquartered in the greater Boston area, Enliven Therapeutics operates in a hub of biopharmaceutical innovation and maintains strategic collaborations with academic institutions and contract research organizations. The company’s management team brings together seasoned executives and scientists with extensive experience in oncology drug discovery and clinical development. Through its focused R&D strategy, Enliven seeks to advance novel precision therapies that address critical unmet needs in cancer treatment.

Key Stats

• Today's Range: $58.97 to $59.89
• 50-Day Range: $48.76 to $61.15
• 52-Week Range: $14.78 to $62.32
• Volume: 115,088 shs
• Average Volume: 1.22 million shs
• Market Capitalization: $4.37 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $75.00
• Consensus Rating: Moderate Buy

Enliven Therapeutics Stock Analysis - MarketRank™

Enliven Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 377th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Enliven Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Enliven Therapeutics has a consensus price target of $75.00, representing about 26.1% upside from its current price of $59.46.

Amount of Analyst Coverage

Enliven Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Enliven Therapeutics are expected to decrease in the coming year, from ($1.69) to ($2.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enliven Therapeutics is -35.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enliven Therapeutics is -35.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enliven Therapeutics has a P/B Ratio of 4.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.62% of the float of Enliven Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Enliven Therapeutics has a short interest ratio ("days to cover") of 6.33.

Change versus previous month

Short interest in Enliven Therapeutics has recently increased by 1.32%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enliven Therapeutics does not currently pay a dividend.

Dividend Growth

Enliven Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.56

News Sentiment

Enliven Therapeutics has a news sentiment score of 1.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Enliven Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for ELVN on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Enliven Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,344,257.00 in company stock.

Percentage Held by Insiders

3.00% of the stock of Enliven Therapeutics is held by insiders.

Percentage Held by Institutions

95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/04/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ELVN
• CIK: 1672619
• Web: imaratx.com
• Phone: 617-927-9989
• Fax: N/A
• Employees: 50
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Enliven Therapeutics: $75.00
• High Price Target: $82.00
• Low Price Target: $64.00
• Potential Upside/Downside: +25.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$103.69 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -18.55%
• Return on Assets: -18.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 64.07
• Quick Ratio: 64.07

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.22 per share
• Price / Book: 4.88

Miscellaneous

• Outstanding Shares: 73,270,000
• Free Float: 71,073,000
• Market Cap: $4.37 billion
• Optionable: Optionable
• Beta: 0.30